The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The role of ALC and early CRS in predicting delayed responses to teclistamab in myeloma
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses a real-world analysis through the US Myeloma Immunotherapy Consortium, which aimed to elucidate factors that can help to predict response to teclistamab treatment in patients with multiple myeloma (MM). The study highlighted that absolute lymphocyte count (ALC) at day 30 and the presence of early cytokine release syndrome (CRS) are early indicators of which patients will respond to treatment by day 90. Dr Banerjee suggests using these predictors to establish whether switching treatment approaches is necessary or whether continuing on teclistamab may bring about a delayed response. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
